Advanced search
Start date

Immunogenicity and safety of CoronaVac vaccine in patients with autoimmune rheumatologic diseases: Juvenile systemic erythemesus lupus

Grant number: 21/06615-3
Support Opportunities:Scholarships in Brazil - Scientific Initiation
Effective date (Start): July 01, 2021
Effective date (End): February 28, 2023
Field of knowledge:Health Sciences - Medicine - Medical Clinics
Principal Investigator:Eloisa Silva Dutra de Oliveira Bonfá
Grantee:Camilla Oliveira Hoff
Host Institution: Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
Associated research grant:15/03756-4 - Assessment of relevance of blood levels of drugs in the monitoring rheumatic autoimmune diseases: safety, effectiveness and adherence to therapy, AP.TEM


The COVID-19 pandemic has progressed rapidly worldwide, reaching lethality of up to 20% in different regions (Garcia LF, 2020). More severe cases were observed in elderly patients with comorbidities, particularly in those with chronic cardiovascular or respiratory diseases, diabetes and hypertension (Garcia LF, 2020; Emmi G, 2020). SARS-Cov-2 infection raised a particular concern in patients with autoimmune rheumatic diseases (ARDD) (Garcia LF, 2020; Emmi G, 2020). Due to chronic inflammatory autoimmune dysregulation and regular use of immunosuppressive drugs (Fernandez-Ruiz R, 2020), these patients were considered at high risk of contracting SARS-CoV-2 and potentially worse prognosis (Fernandez-Ruiz R, 2020). Vaccine efficacy studies are needed to verify the immunogenicity of COVID-19 vaccine in immunosuppressed patients with rheumatologic disease. In addition, it is relevant to evaluate the safety of the vaccine in these populations, as well as the possibility of reactivation of the rheumatologic disease itself. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items

Please report errors in scientific publications list by writing to: